Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.08 USD
Change Today -0.02 / -0.65%
Volume 1.5M
EXEL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

exelixis inc (EXEL) Snapshot

Open
$3.09
Previous Close
$3.10
Day High
$3.14
Day Low
$3.07
52 Week High
07/28/14 - $4.55
52 Week Low
12/23/14 - $1.26
Market Cap
603.4M
Average Volume 10 Days
2.4M
EPS TTM
$-1.37
Shares Outstanding
195.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXELIXIS INC (EXEL)

exelixis inc (EXEL) Related Businessweek News

No Related Businessweek News Found

exelixis inc (EXEL) Details

Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is also evaluating cabozantinib in various development programs comprising approximately 45 clinical trials, including 2 ongoing phase 3 pivotal trials focusing on metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC). In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase 3 pivotal trial evaluating in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

98 Employees
Last Reported Date: 03/2/15
Founded in 1994

exelixis inc (EXEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $755.2K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $318.9K
Executive Vice President and Chief Medical Of...
Total Annual Compensation: $513.9K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $407.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $380.8K
Compensation as of Fiscal Year 2014.

exelixis inc (EXEL) Key Developments

Exelixis, Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Financial Guidance for the First Six Months of 2015

Exelixis, Inc. reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2014. Net revenues for the quarter ended December 31, 2014 were $7.4 million, compared to $4.3 million for the comparable period in 2013. The decrease in contract and license revenue reflects the company’s full recognition of all revenues from its collaboration agreements with Bristol-Myers Squibb Company in the third quarter of 2013. Net loss was $58.0 million, or $0.30 per share, basic and diluted, compared to $70.7 million, or $0.38 per share, basic and diluted for the comparable period in 2013. The decreased net loss for the quarter was primarily due to decreases in research and development expenses and selling, general and administrative expenses, and an increase in product revenues, which was partially offset by an increase in restructuring charges. Loss from operations was $46,208,000 compared to $59,514,000 a year ago. Loss before income taxes was $58,135,000 compared to $70,842,000 a year ago. Net revenues for the year ended December 31, 2014 were $25.1 million, compared to $31.3 million for the comparable period in 2013. Net loss for the year ended December 31, 2014 was $268.5 million, or $1.38 per share, basic and diluted compared to $244.8 million, or $1.33 per share, basic and diluted for the comparable period in 2013. The increased net loss for the year was primarily due to decreases in contract and license revenue, increases in research and development expenses and restructuring charges, which was partially offset by an increase in product revenues. Loss from operations was $224,458,000 compared to $200,732,000 a year ago. Loss before income taxes was $268,724,000 compared to $244,856,000 a year ago. Given that the company anticipates key clinical milestones in the second quarter of this year that will influence operating expenses for the remainder of 2015, the company is currently only providing guidance for the first six months of 2015. The company anticipates that operating expenses for the first six months of 2015 to be in a range of $70 million to $80 million. This range includes approximately $5 million in restructuring charges in the first half of 2015 primarily related to building exit costs. Taking into account the expected extension of the maturity date of the company’s indebtedness under its note purchase agreement with Deerfield to July 1, 2018 from July 1, 2015, the company expects that its current cash and cash equivalents, short- and long-term investments and product revenues are sufficient to fund its operations through the end of 2015. The company has until March 31, 2015 to exercise its option to extend the maturity date of the Deerfield indebtedness, as provided for by the January 2014 amendment to the note purchase agreement. Any exercise of the extension option by the company will be subject to customary conditions set out in the note purchase agreement, as amended.

Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma

Exelixis, Inc. announced that the U.S. Food and Drug Administration has accepted for review Genentech’s New Drug Application for cobimetinib in combination with vemurafenib for patients with unresectable or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib is a specific MEK inhibitor that was discovered by Exelixis and is now the subject of a worldwide co-development agreement between Exelixis and Genentech, a member of the Roche Group.

Exelixis, Inc. to Report Q4, 2014 Results on Feb 24, 2015

Exelixis, Inc. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Feb 24, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXEL:US $3.08 USD -0.02

EXEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $1.96 USD +0.01
Curis Inc $2.96 USD -0.01
Cytokinetics Inc $7.25 USD -0.18
Evotec AG €3.87 EUR +0.017
Rigel Pharmaceuticals Inc $4.88 USD +0.55
View Industry Companies
 

Industry Analysis

EXEL

Industry Average

Valuation EXEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXELIXIS INC, please visit www.exelixis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.